The issue of HIV drug resistance impacts greatly on treatment regimens for HIV and AIDS patients, therefore impacting commercially on HIV therapeutic products globally. The growth in resistance monitoring is a development that HIV pharmaceutical companies need to be aware of and initiate collaborative ventures to improve product uptake. Relevant case reports and strategic proposals are discussed.
Scope
Explanation of why HIV drug resistance emerges, how it is monitored and what its impact is from both a clinical and commercial aspect
Provides an overview of all resistance mutations for all HIV drugs on the market and these affect product lifetime and development
Detailed description of entry inhibitors and their mechanisms of action and how resistance will affect this particular class of HIV drug
Identifies specific areas on which to focus on in the field of resistance and gives strategic recommendations
Report Highlights
The issue of inconcordance of plasma and sanctuary site viral evolution is a critical one that is being overlooked in this arena. Manufacturers need to be aware of the bioavailability of their drugs at these sites, as it will affect long-term resistance, efficacy and product lifetime.
The trend towards monitoring of virus-dependant factors such as coreceptor density and alterations in envelope protein distinct from the target site is growing and needs to be monitored carefully to facilitate probability of treatment success with this particular class of HIV therapy.
Datamonitor believes that relegation of entry inhibitors to salvage therapy is a suboptimal use of this novel class of HIV therapeutic drugs.
Reasons to Purchase
Understand HIV drug resistance, the monitoring assays available and its impact on clinical and commercial success of a drug
Be aware of the current and potential HIV entry inhibitors in the market and the impact of drug resistance in this class
Gives strategic recommendations for companies to focus on to overcome HIV drug resistance-related issues
